Twist Bioscience (TWST) Receivables (2018 - 2026)

Twist Bioscience (TWST) has reported Receivables for 9 consecutive years, with $65.1 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Receivables rose 30.5% year-over-year to $65.1 million in Q2 2026; TTM through Jun 2026 was $65.1 million, a 30.5% increase from a year earlier, with the FY2025 full-year figure at $57.3 million, up 64.2% from the prior year.
• Receivables was $65.1 million for Q2 2026 at Twist Bioscience, down from $81.3 million in the prior quarter.
• Over five years, Receivables peaked at $81.3 million in Q1 2026 and troughed at $32.0 million in Q2 2024.
• A 5-year average of $47.7 million and a median of $47.1 million in 2022 frame the typical range for Receivables.
• Across the five-year window, Receivables sank 33.56% in 2024 and jumped 64.2% in 2025, its largest moves.
• Over 5 years, Receivables stood at $49.7 million in 2022, then retreated by 28.85% to $35.4 million in 2023, then gained by 11.2% to $39.3 million in 2024, then grew by 27.34% to $50.1 million in 2025, then climbed by 29.95% to $65.1 million in 2026.
• The last three Receivables figures came in at $65.1 million (Q2 2026), $81.3 million (Q1 2026), and $50.1 million (Q4 2025), per Business Quant data.